Clinical Trial Update: Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating zoledronate to prevent skeletal-related events in men with metastatic prostate cancer on androgen deprivation therapy; study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of the Prostate
• Prostate Cancer

Drugs mentioned

• Zoledronate (zoledronic acid)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Metastatic Cancer, Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-10-30